ABSTRACT
Aim: We performed a meta-analysis of S-1-containing regimens versus control in the management of locally advanced/metastatic non-small-cell lung cancer. Methodology: Eligible studies included randomized studies evaluating S-1-containing regimens in the settings of locally advanced, first-line metastatic or second-line metastatic non-small-cell lung cancer. Results: Pooled odds ratio for overall response rate was 1.09 (95% CI: 0.85–1.38; p = 0.2), the pooled hazard ratio for progression-free survival was 0.98 (95% CI: 0.88–1.09; p = 0.69) and the pooled hazard ratio for overall survival was 0.98 (95% CI: 0.88–1.10; p = 0.75) for S-1-based regimens versus control. Moreover, the relative risk of febrile neutropenia was 0.34 (95% CI: 0.20–0.59; p = 0.0001). Conclusion: Our meta-analysis has demonstrated that S-1-based regimens are associated with similar efficacy outcomes and better hematological tolerability.
KEYWORDS:
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.